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Abstract
Background Blood–retinal barrier breakdown secondary to
retinal detachment and retinal detachment repair is a factor
in the pathogenesis of proliferative vitreoretinopathy
(PVR). We wished to investigate whether an estimated
700 to 1000 ng/ml subretinal dexamethasone concentration
at the time of surgery would decrease the blood–retinal
barrier breakdown postoperatively.
Methods Prospective, placebo-controlled, double blind
clinical trial. In 34 patients with rhegmatogenous retinal
detachment scheduled for conventional scleral buckling
retinal detachment surgery, a subconjunctival injection of
0.5 ml dexamethasone diphosphate (10 mg) or 0.5 ml
placebo was given 5–6 hours before surgery. Differences in
laser flare photometry (KOWA) measurements taken 1, 3
and 6 weeks after randomisation between dexamethasone
and placebo were analysed using mixed model ANOVA,
while correcting for the preoperative flare measurement.
Results Six patients did not complete the study, one
because of recurrent detachment within 1 week, and five
because they missed their postoperative laser flare visits.
The use of dexamethasone resulted in a statistically
significant decrease in laser flare measurements at the 1-
week postoperative visit.
Conclusion The use of a preoperative subconjunctival
injection of dexamethasone decreased 1-week postoperative
blood–retina barrier breakdown in patients undergoing
conventional scleral buckling retinal detachment surgery.
This steroid priming could be useful as a part of a peri-
operative regime that would aim at decreasing the incidence
of PVR.
Keywords Preoperative . Subconjuctival injection .
Dexamethasone . PVR . Blood–retina barrier . Breakdown
Introduction
Proliferative vitreoretinopathy (PVR) remains the major
cause of ultimate surgical failure in patients with rhegma-
togenous retinal detachment [9, 19]. Retinal pigment
epithelium (RPE) cell dispersion and inflammatory changes
secondary to breakdown of the blood–retinal barrier (BRB)
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have been implicated as important pathogenetic mecha-
nisms in the development of PVR [4, 6, 7, 17].
Studies in animals [5, 18] have reported that intravitreal
corticosteroids may be useful in the prevention of prolifer-
ative vitreoretinopathy. Clinical reports have suggested the
same effect using either systemic [15] or intravitreal [31]
steroids. This was mainly attributed to their attenuating
effect on blood–retinal barrier breakdown and their inhibit-
ing effect on proliferation of RPE cells and fibroblasts,
which are thought to be transformed RPE cells, and as
myofibroblasts responsible for the contractile properties of
PVR membranes.
Studies in animals have suggested that pretreating with
steroids was more effective in PVR prevention than
treatment started at the time of injury or later [5]. Adequate
intraocular concentrations of corticosteroids at the time of
surgery might reduce the blood–retina barrier breakdown
induced by the surgical trauma during cryotherapy, drain-
age of subretinal fluid, or intravitreal gas injection, and
thereby decrease the incidence of PVR.
Weijtens et al. showed in patients that among external
routes of administration, a subconjunctival injection of
dexamethasone resulted in the highest intravitreal and
subretinal fluid concentrations [25, 26, 28–30].
Therefore we wished to study, in patients undergoing
conventional scleral buckling retinal detachment surgery,
whether a subconjunctival injection of dexamethasone prior
to surgery would decrease postoperative blood–retinal
barrier breakdown as measured by laser flare photometry.
Materials and methods
Consecutive patients admitted to the Rotterdam Eye
Hospital with a rhegmatogenous retinal detachment sched-
uled for scleral buckling were included in the study.
Exclusion criteria were therapy with systemic or local
steroids, glaucoma, diabetes, and other vascular retinopa-
thies. This prospective, randomized, placebo-controlled,
double blind study had been approved by the Institutional
Review Board (NRT 194, ISRCTN31308983).
Preoperative investigation All patients underwent a com-
prehensive ophthalmological examination, including best-
corrected visual acuity tested with an EDTRS chart.
Specific items were noted and entered into a database: lens
status (phakic or pseudophakic), the presence of vitreous
blood, number of quadrants of detached retina, presence
and number of horseshoe tears, presence of PVR according
to 1983 classification [1], as well as aqueous laser flare
meter measurements (Kowa Company, Ltd, Tokyo, Japan).
Patients were examined 30 minutes after mydriasis with 5%
phenylephrine and 1% tropicamide, and always before the
application of fluorescein for intraocular pressure measure-
ment. For each eye, five measurements were averaged.
Surgical Technique Six hours before the planned surgery,
all patients received under topical anaesthesia (cocaine
and oxybuprocaine eye drops) a subconjunctival injection
0.5 ml placebo NaCl (Delftse Apotheek, Apotheek
Westblaak), or 0.5 ml dexamethasone diphosfate 20 mg/ml
(Delftse Apotheek, Apotheek Westblaak). A 30-gauge
needle was used, 4 mm from the limbus, with closure of
the injection site by a cottonwool tip for 10 seconds.
Randomization had been performed by opening an
envelope with study medication that contained either
verum or placebo, of which our trial-pharmacist held the
code; therefore, surgeons and technicians alike were
blinded to the nature of the subconjunctival injection.
All patients underwent a standard scleral buckling
procedure as described before [22, 23]. A silicone band
was placed under the four rectus muscles at the presumed
area of the vitreous base, and the sclera under retinal tears
and breaks was indented with either a circumferential
(278, 277, 287 Mira Silastic) or radial (7.5 mm sponge)
buckle. Subretinal fluid was drained in all patients.
Retinopexy of the tears or breaks was done by cryocoa-
gulation during surgery, or with an argon laser mounted on
a slit lamp between 2 and 6 weeks after the surgery,
according to the surgeons’ preference. In some patients, an
air or gas (air/SF6) tamponade was used. All patients
received a 2 mg dexamethasone and 1 mg gentamycin
subconjunctival injection at the end of the surgery.
Follow-up All patients received the same postoperative
treatment, prednisolone acetate 1% eyedrops in a tapering
dose over 6 weeks. ETDRS vision, a fundus exam and laser
flare measurements were taken at 1, 3 and 6 weeks.
The treatment effects of dexamethasone versus place-
bo on flare were analyzed after logarithmic transforma-
tion of flare (photon counts/ms). Hence, effects were
specified as percentage differences in photon counts/ms.
Mixed model ANOVA was used to estimate and test for
statistical significance the effects on flare of week
(weeks 1, 3 and 6), treatment (dexamethasone, placebo),
and their interaction. The baseline measurement of flare
at week 0 was entered as covariable in the model, along
with its interaction with week. No structure was imposed
on the (co)variances of the three repeated measurement
of flare.
Results
A total of 34 patients (19 males/ 15 females) were included
from 1 February 2003 to 1 February 2004. The age of the
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patients ranged from 18 to 76 years (mean 54 years).
Follow-up ranged from 6 to 8 months. Six patients did not
complete the study as planned. One patient had a redetach-
ment due to an undetected tear within the first weeks, and
five patients missed two or more of their laser flare follow-
up visits; none of these five patients suffered new breaks or
a redetachment.
Of the remaining patients, 15 were in the placebo group
and 13 in the dexamethasone group. The various baseline
characteristics, such as preop vision, macula on or off,
quadrants involved, type of breaks, or variables depending
on the surgical procedure such as cryocoagulation or
postoperative laser, were equally distributed between the
dexamethasone-treated patients and the placebo group
(Table 1). At the last examination, two patients given
placebo and two patients given dexamethasone had an
intraocular pressure between 20 and 25 mmHg.
In the placebo group, laser flare measurements on
average increased during the first week and decreased
thereafter. In the dexamethasone group, there was a steady
decrease as from week 0 (Table 2, summary raw data). The
mixed model ANOVA yielded the following results. The
treatment effect on flare of dexamethasone versus placebo
differed significantly between the three weeks (P=0.007).
Table 1 Baseline characteristics of the two groups
Age Refr IOL Preop vision Preop PVR Macula Quadrants Holes Horseshoe tears Surgeon Laser Cryo
Dexa patients
1 65 plan 0.016 off 3 1 E x
2 21 plan 1.6 on 2 1 C x
3 44 nn 0.1 off 2 2 B x
4 72 plan 0.003 off 2 2 C x
5 60 -5 0.25 off 1 1 D
6 56 -5 0.016 off 2 1 D x
7 66 plan 0.016 off 2 1 D x
8 40 -3 0.016 off 2 2 C x
9 47 -10 1.0 on 1 1 D x
10 71 -3 + 0.003 off 3 2 B x
11 49 -9 0.15 off 1 1 E x
12 65 nn 0.25 off 2 1 D x
13 81 plan 0.7 A on 2 1 C x
Placebo patients
1 77 -2 0.003 off 3 E x
2 55 plan 0.016 off 3 1 C x
3 61 -4 1.0 on 1 1 D x
4 47 -6 1.0 on 1 1 E x
5 29 -3 0.25 A off 1 2 C x
6 59 -8 1.0 on 1 1 B x
7 40 -.7 0.7 part 2 1 D x
8 64 plan 0.003 C1 off 2 1 B x
9 56 -5 0.003 off 2 1 C x
10 62 -6 0.003 off 2 1 C x
11 17 plan 0.6 part 1 dialysis D x
12 30 +2 0.5 part 1 1 B x
13 59 -7 1.0 on 1 1 B x
14 71 nn 0.1 off 2 2 x
15 22 -6 1.0 on 1 1 A x
refr: refractive error
plan: plano refraction
IOL: intraocular lens
nn: not noted
part: partially off/partially attached
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The effect of baseline flare on flare during treatment also
decreased significantly across the 3 weeks (P=0.019). Only
at week 1 was a significant reduction of dexamethasone
relatively to placebo seen: flare was 48.3% lower under
dexamethasone, adjusted for baseline flare (95% CI: 72.1%
lower to 4.4% lower; P=0.037); see the mixed model
ANOVA estimates in Table 2.
Discussion
Intravitreal dexamethasone has been shown to reduce the
number of tractional detachments in experimental animal
models of PVR by cell-injection [18, 20]. Studies in
animals and patient have suggested that pretreating with
steroids was more effective in PVR prevention than
treatment started at the time of injury or later [5]. It was
speculated that the decrease of BRB breakdown and
inhibition of the proliferation of RPE cells accounted for
this effect. Dexamethasone has a biphasic effect on RPE
cell proliferation in vitro, i.e. rather a stimulatory effect
with lower concentrations (ng per ml) [12, 32, 33], and an
inhibitory effect on proliferation of RPE in vitro at
relatively high concentrations (mg per ml, not reached by
peribulbar or systemic administration, only by intravitreal
injection).
Corticosteroids bind to intracellular receptors and act on
inflammation by inhibiting the synthesis of immunoregula-
tory proteins such as cytokines. The magnitude of this
response is directly proportional to the number of occupied
steroid receptors and is therefore dose-dependant [3]. Given
the studies by Weijtens et al. in patients with rhegmotog-
enous retinal detachments, macular puckers and macular
holes, which showed that a subconjunctival dexamethasone
injection would result in optimal concentrations in the
vitreous (72.5 ng/ml after 2.5 mg dexamethasone [25]) and
the subretinal fluid (367 ng/ml after 2.5 mg dexamethasone
[27]) between 3 and 6 hours after injection; and assuming
that the time interval between binding to the steroid
receptor and transcription of effector proteins would take
less than 2 hours, we timed the subconjunctival injection 5
to 6 hours before surgery. It may well be that only direct
steroid-receptor ligand prevention of nuclear factor kappa B
pro-inflammatory effect is acting within this time interval
[8]. The estimated dexamethasone concentration levels of
700 to 1000 ng/ml reached with our injection would be
effective in decreasing BRB by inducing tight-junction
formation [2] and the modulation of cytokine release[11],
but not for cell growth inhibition [12, 16, 32, 33].
The disadvantage of using dexamethasone is its short
half-life, limiting the time interval in which the drug can
be used to minimize the surgically induced inflammation.
For clinical purposes, a longer-acting steroid would
allow a more flexible preoperative administration treat-
ment moment, as well as a longer treatment effect, but it
would be at the price of a higher incidence of raised
intraocular pressure and a lower subretinal and vitreous
concentration at the time of surgery. To ensure a
continuous affective steroid concentration following
preoperative priming by a subconjunctival dexametha-
sone injection, pre-operative intravitreal injection of
longer-acting triamcinolone, or a sustained release im-
plant might be an feasible option [14, 34].
A drawback of our study was the small number of
patients enrolled. By changes in admission policy right at
the start of our study, patients were no longer admitted the
day before surgery but were treated on an ambulatory basis.
Potential study patients were asked to come in at least 6
hours earlier then the normal admission time, which was a
significant inconvenience and reduced the number of
patients willing to participate in the study. Therefore, we
could only use a quantitative surrogate marker, i.e. laser
flare, as a measurement of BRB breakdown, instead of the
originally intended rate of PVR.
Table 2 Laser flare measurements (counts per seconds) at four visits, and their relative percentage in patients treated with dexamethasone when
compared to patients treated with placebo
Week Treatment Summary raw data Mixed model ANOVA estimates
N Median Min. Max. % dexa vs placebo 95% CI P-value
0 Placebo 16 10.2 2.4 94.0
Dexa 13 10.4 7.7 95.6
1 Placebo 16 16.7 3.1 56.9
Dexa 12 8.1 1.0 58.6 -48.3% -72.1% to -4.4% 0.017
3 Placebo 15 9.6 2.2 16.1
Dexa 12 7.1 3.1 48.9 +2% -37.8% to +67.2% 0.94
6 Placebo 15 5.7 0.9 14.0
Dexa 12 6.2 1.6 12.4 +17.6% -35.1% to +113% 0.58
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Laser flare photometry, however, allows precise and
non-invasve quantification of the aqueous protein content.
Although laser flare photometry has been used mainly to
study anterior segment inflammation, it has been shown to
be useful in monitoring posterior segment disease [10, 13,
21, 23, 24].
This study showed that a single injection of dexa-
methasone, injected at an estimated optimized time
interval preoperatively, significantly decreased blood–
retinal barrier breakdown at 1 week induced by a scleral
buckling procedure. We cannot exclude, however, that a
similar effect would have been achieved by supplying the
same dose at the time of surgery or with a longer
interval before surgery. To answer that comprehensively,
a four-armed study would have been necessary. Never-
theless, our findings may help in designing a feasible,
optimal perioperative steroid regime, which might include
a sustained release device or intravitreal injection at the
end of conventional surgery or, in the case that
vitrectomy is chosen to treat the retinal detachment,
steroids in the peroperative intravitreal infusion. However,
surgically induced inflammation is only one risk factor
among others in the development of PVR. Larger studies
including greater numbers of patients, a more sustained
dexamethasone regime, and longer follow-up are needed to
demonstrate whether pharmacologically decreasing the
blood–retina barrier breakdown ultimately may lead to a
lower incidence of PVR.
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